Search Results
Mar 24, 2026, 08:47 ET Ellenby Technologies Inc. Acquires Assets of InOne Technology LLC
availability. The integrated team is also expected to accelerate development, resulting in several new offerings for the market in the coming months.Gene Ostendorf, Founder, President and CEO of InOne Technology, LLC, remarked, "InOne and Ellenby have been working together for most of our company's mutual
More news about: Ellenby Technologies, Inc.
Mar 24, 2026, 08:30 ET Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month
fluoropyrimidine-based therapies such as capecitabine and fluorouracil remain a cornerstone of treatment. However, certain inherited variants in the DPYD gene can reduce dihydropyrimidine dehydrogenase (DPD) enzyme activity, increasing the risk of severe, and in some cases life-threatening, toxicity from these
More news about: Caris Life Sciences
Mar 24, 2026, 07:50 ET Partillion Bioscience Advances a New Era of Cell-Cell Interaction Mapping at the 2026 Cell-Cell Symposium
its website as an early demonstration of this approach, where researchers can explore Cell-Cell-seq data, including differentially expressed genes, gene correlations, and other transcriptional features linked to cell-cell interactions."The fundamental unit of multicellular biology is the interaction
More news about: Partillion Bioscience
Mar 24, 2026, 05:16 ET /C O R R E C T I O N -- Kindeva/
the sector, such as Frederick Banting & Charles Best, the creators of Isolated insulin and Emmanuelle Charpentier, the co-developer of CRISPR-Cas9 gene editing.Jeremy Tidmarsh, Vice President of Kindeva's MDI business unit, said: "From its very beginnings, Kindeva (formerly Riker Laboratories/3M
More news about: Kindeva
Mar 23, 2026, 17:30 ET Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis
SYDNEY, March 23, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in its Phase 1b KOANEWA trial evaluating CTx1000, an investigational
More news about: Celosia Therapeutics
Mar 23, 2026, 17:30 ET Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis
SYDNEY, March 23, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in its Phase 1b KOANEWA trial evaluating CTx1000, an investigational
More news about: Celosia Therapeutics
Mar 23, 2026, 09:00 ET Orsini to Serve as Single-Source Specialty Pharmacy Partner for Glaukos' Epioxa™
most."About OrsiniProviding patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary
More news about: Orsini
Mar 23, 2026, 08:30 ET Fast-Tracking IVT mRNA Candidate Selection Through Smarter RNA Design, Upcoming Webinar Hosted by Xtalks
downstream applications. This webinar will highlight how an integrated in vitro transcribed (IVT) RNA workflow can accelerate progression from gene to mRNA, including rapid options for time-sensitive projects, without compromising robust quality control and process design.
More news about: Xtalks
Mar 23, 2026, 08:00 ET Greenland Mines Secures Additional 180-Day Period for Nasdaq Bid Price Compliance
requirements.Greenland Mines remains committed to maintaining its Nasdaq listing and advancing the development of its strategic mineral resources and cell and gene therapy assets.About Greenland Mines LtdGreenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Natural
More news about: Greenland Mines Ltd
Mar 23, 2026, 08:00 ET Immunexpress Presenting at the Society of Critical Care Medicine (SCCM) 2026 Critical Care Congress Showing SeptiCyte RAPID® High Correlation with Blood Culture Positive Sepsis Patients
improving outcomes for patients with suspected sepsis. The company's SeptiCyte® technology assesses a patient's dysregulated immune response by quantifying gene expression from whole blood, delivering actionable information during the critical early hours of sepsis evaluation. By enabling earlier and more confident
More news about: Immunexpress, Inc.
Mar 23, 2026, 08:00 ET Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa
Inc.) and Canada (Sumitomo Pharma Canada, Inc.) focused on addressing patient needs in oncology, urology, women's health, rare diseases, cell & gene therapies and CNS. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, we aim to accelerate
More news about: Sumitomo Pharma America
Mar 23, 2026, 07:24 ET Interna Therapeutics Announces Human Challenge Trial Agreement with the University of Oxford to Advance Intranasal MNM-siRNA SARS-CoV-2 Prophylaxis Program
its proprietary MNM technology to deliver siRNA directly into the epithelial cells of respiratory tract, where it silences a highly conserved viral gene essential for replication. The drug is designed for convenient self-administration via an intranasal spray, offering the potential for pre-exposure
More news about: Interna Therapeutics
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
survival (PFS) events are observed, which the Company continues to anticipate will occur in 2026.Sickle Cell Disease (SCD) & Gene TherapyAnnounced that a poster featuring final results from a Phase 1 clinical trial (
More news about: BioLineRx Ltd.
Mar 23, 2026, 07:00 ET Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
Mar 23, 2026, 06:26 ET Karmanos Cancer Institute Becomes First and Only Free-Standing Cancer Center to Treat Hemophilia B with New Gene Therapy
here.How Does the Gene Therapy Work?"The gene coding for factor IX is placed into a vector containing an inactive viral capsid. We then infuse it into the patient intravenously,
More news about: Karmanos Cancer Institute
Mar 23, 2026, 03:31 ET Diamyd Medical enters into equity financing agreements with new U.S. sector specialist investors for up to USD 125 million and announces full enrollment in Phase 3 trial
antigen-specific immune tolerance to GAD65 and preserve endogenous insulin production in individuals with type 1 diabetes who carry the HLA DR3-DQ2 gene. Retogatein has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically
More news about: Diamyd Medical AB
Mar 23, 2026, 03:29 ET Diamyd Medical enters into equity financing agreements with new U.S. sector specialist investors for up to USD 125 million and announces full enrollment in Phase 3 trial
antigen-specific immune tolerance to GAD65 and preserve endogenous insulin production in individuals with type 1 diabetes who carry the HLA DR3-DQ2 gene. Retogatein has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically
More news about: Diamyd Medical AB
Mar 23, 2026, 01:48 ET Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients
BioMed, said, "Belief BioMed focuses on the cutting-edge gene therapy field, with our product pipeline covering the rare and common diseases, striving to fill a large number of unmet clinical needs. In 2025, we successfully launched China's first gene therapy for Hemophilia B, BBM-H901, providing a novel
More news about: Belief BioMed
Mar 22, 2026, 09:28 ET RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Faruqi & Faruqi, LLP
Mar 20, 2026, 16:30 ET QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Mar 20, 2026, 07:35 ET Mit RiboPepSTAR™ geht Ribo über die Leber hinaus - und ermöglicht so den gezielten Transport von siRNA in verschiedene Organe
erschließen. Parallel dazu treibt Ribo seine Multi-Target-siRNA-Plattform voran, die es ermöglicht, mit einem einzigen Molekül zwei oder mehr Gene gleichzeitig zu silenzieren. Die Dual-Target-siRNAs von Ribo erreichen Knockdown-Werte, die mit denen von Single-Target-Molekülen vergleichbar sind,
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 20, 2026, 07:32 ET Avec RiboPepSTAR™, Ribo permet l'administration ciblée de petits ARN interférents (pARNi) à plusieurs organes autres que le foie
RiboPepSTAR™ démontrent une absorption sélective dans les cellules tubulaires proximales à travers les modèles, et jusqu'à 80 % de réduction d'expression du gène cible ont été atteints, des rongeurs aux primates non humains. La preuve de concept physiologique a ensuite été validée dans plusieurs modèles de maladies,
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 20, 2026, 06:02 ET 12 Press Releases You Need to See This Week
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed TherapeuticsLaunched in collaboration with Anthropic, Ultima Genomics and PacBio, and powered by NVIDIA AI infrastructure, the Trillion Gene Atlas aims to expand known evolutionary genetic diversity
More news about: PR Newswire
Mar 20, 2026, 03:18 ET Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs
targeting Using RiboPepSTAR™, preclinical studies demonstrate selective uptake in proximal tubular cells across models, and up to 80% target gene knockdown (KD) has been achieved, from rodents to NHPs. Physiological proof of concept was further validated in several disease models, such as type
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 20, 2026, 02:41 ET Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs
targeting Using RiboPepSTAR™, preclinical studies demonstrate selective uptake in proximal tubular cells across models, and up to 80% target gene knockdown (KD) has been achieved, from rodents to NHPs. Physiological proof of concept was further validated in several disease models, such as type
More news about: Suzhou Ribo Life Science Co., Ltd.